Immunitybio Historical Financial Ratios
| IBRX Stock | USD 5.04 0.06 1.18% |
Immunitybio is lately reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 1.8 K or Invested Capital of 0.0 will help investors to properly organize and evaluate Immunitybio financial condition quickly.
Immunitybio |
About Immunitybio Financial Ratios Analysis
ImmunitybioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunitybio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunitybio financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunitybio history.
Immunitybio Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Immunitybio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunitybio sales, a figure that is much harder to manipulate than other Immunitybio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Immunitybio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunitybio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.At this time, Immunitybio's Price To Sales Ratio is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 1.74 in 2024, despite the fact that PTB Ratio is likely to grow to (4.13).
| 2023 | 2024 (projected) | Graham Number | 5.46 | 7.84 | Receivables Turnover | 0.2 | 0.19 |
Immunitybio fundamentals Correlations
Click cells to compare fundamentals
Immunitybio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunitybio fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 659.51 | 8.4K | 2.5K | 8.4K | 4.1K | 6.7K | |
| Ptb Ratio | 12.03 | (42.63) | (9.77) | (4.53) | (4.35) | (4.13) | |
| Days Sales Outstanding | 94.5K | 50.22 | 520.93 | 2.9K | 1.9K | 1.8K | |
| Book Value Per Share | 0.31 | (0.31) | (0.63) | (1.12) | (1.15) | (1.09) | |
| Free Cash Flow Yield | (0.83) | (0.11) | (0.0339) | (0.13) | (0.22) | (0.16) | |
| Operating Cash Flow Per Share | (0.8) | (0.4) | (0.45) | (0.71) | (0.72) | (0.76) | |
| Stock Based Compensation To Revenue | 1.55 | 3.61 | 61.22 | 167.41 | 79.04 | 75.09 | |
| Capex To Depreciation | 0.31 | 0.13 | 2.36 | 5.44 | 1.65 | 1.74 | |
| Pb Ratio | 12.03 | (42.63) | (9.77) | (4.53) | (4.35) | (4.13) | |
| Ev To Sales | 659.21 | 8.8K | 3.0K | 11.0K | 4.8K | 7.0K | |
| Free Cash Flow Per Share | (0.41) | (0.45) | (0.79) | (1.09) | (0.78) | (0.82) | |
| Roic | (1.15) | (1.63) | (0.82) | (1.56) | (3.83) | (3.64) | |
| Net Income Per Share | (1.22) | (0.42) | (0.59) | (0.9) | (1.04) | (1.15) | |
| Research And Ddevelopement To Revenue | 50.86 | 230.59 | 209.81 | 1.0K | 373.58 | 332.68 | |
| Capex To Revenue | 1.95 | 2.76 | 35.93 | 414.13 | 49.17 | 46.71 | |
| Cash Per Share | 0.13 | 0.25 | 0.81 | 0.27 | 0.52 | 0.5 | |
| Pocfratio | (9.55) | (29.74) | (8.62) | (6.01) | (6.96) | (7.31) | |
| Interest Coverage | (26.39) | (24.34) | (22.24) | (5.53) | (2.8) | (2.94) | |
| Capex To Operating Cash Flow | (0.0282) | (0.009719) | (0.12) | (0.29) | (0.0834) | (0.0876) | |
| Pfcf Ratio | (9.29) | (29.46) | (7.68) | (4.64) | (6.43) | (6.75) | |
| Income Quality | 0.95 | 0.77 | 0.78 | 0.81 | 0.63 | 0.49 | |
| Roe | (1.33) | 1.87 | 1.44 | 0.93 | 0.99 | 1.04 | |
| Ev To Operating Cash Flow | (9.54) | (31.15) | (10.32) | (7.84) | (8.22) | (8.63) | |
| Pe Ratio | (9.07) | (22.78) | (6.76) | (4.86) | (4.38) | (4.6) | |
| Return On Tangible Assets | (0.57) | (1.22) | (1.02) | (0.75) | (1.2) | (1.26) | |
| Ev To Free Cash Flow | (9.28) | (30.85) | (9.19) | (6.06) | (7.59) | (7.97) | |
| Earnings Yield | (0.11) | (0.0439) | (0.15) | (0.21) | (0.23) | (0.24) | |
| Intangibles To Total Assets | 0.0844 | 0.006609 | 0.003028 | 0.0552 | 0.0339 | 0.0322 | |
| Net Debt To E B I T D A | 0.004639 | (1.28) | (1.47) | (1.85) | (1.06) | (1.0) | |
| Current Ratio | 4.82 | 1.64 | 0.91 | 0.28 | 5.05 | 4.79 | |
| Tangible Book Value Per Share | 0.28 | (0.31) | (0.63) | (1.17) | (1.19) | (1.13) | |
| Graham Number | 1.72 | 2.03 | 3.55 | 5.12 | 5.46 | 7.84 | |
| Shareholders Equity Per Share | 0.31 | (0.31) | (0.62) | (1.12) | (1.15) | (1.1) | |
| Debt To Equity | 0.12 | (2.12) | (2.67) | (1.5) | (1.16) | (1.22) | |
| Capex Per Share | 0.17 | 0.0112 | 0.004356 | 0.0862 | 0.25 | 0.0601 | |
| Graham Net Net | 0.0768 | (0.64) | (1.01) | (1.73) | (1.62) | (1.53) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.